Evolution of clinical guidelines for ITP: Role of Romiplostim
|
|
- Alexander Clarke
- 5 years ago
- Views:
Transcription
1 Slovenian Haematological Society 16 April 2010, Podčetrtek Evolution of clinical guidelines for ITP: Role of Romiplostim Dr. Roberto Stasi Department of Haematology St George's Hospital London
2 Is there a need for new guidelines for ITP? Existing guidelines outdated (ASH, 1996; BCSH 2003) Little evidence based on randomized trials and many recommendations based on expert opinion UK and US practice varies New drugs available Countries with limited resources (alternative approaches)
3
4 Assessment of evidence Computer-assisted search of the literature Papers were graded using a specific scoring system Randomized controlled trials (RCTs) were graded as providing the highest level of evidence Case studies and expert opinion the lowest. Grades of recommendation were based on the supporting evidence levels
5 ITP: Definition Isolated thrombocytopenia (Plts <100 x 10 9 /l) with otherwise normal CBC and peripheral smear Previous criteria: Plts <150 x 10 9 /l No other conditions or factors that can cause (or be associated with) thrombocytopenia Previous criteria: same Rodeghiero et al. Blood 2009;113:
6 Isolated thrombocytopenia: initial assessment Full clinical history Determine type of bleeding and family history Examine patient Assess type and severity of bleeding Other presenting features Exclude other conditions that might cause Laboratory investigations Determine the risk: treatment is indicated? Previous guidelines: same
7 Laboratory investigations Basic (mandatory/highly recommended) Tests of potential utility Tests of unproven benefit
8 Basic evaluation Tests of potential utility Patient/family history Glycoprotein-specific antibody TPO Physical examination Complete blood count and reticulocyte count Peripheral blood film Quantitative immunoglobulin level measurement* Bone marrow examination (in selected patients) Blood group (Rh) Direct antiglobulin test H. Pylori** HIV** HCV** Antiphospholipid antibodies (including anticardiolipin and lupus anticoagulant) Anti-thyroid antibodies and thyroid function Pregnancy test in women of childbearing potential Antinuclear antibodies Viral PCR for parvovirus and CMV Tests of unproven benefit Reticulated platelets PalgG Bleeding time Platelet survival study Serum complement *Quantitative immunoglobulin level measurement should be considered in children with ITP and is recommended in those children with persistent of chronic ITP as part of reassessment evaluation **Recommended by the majority of the panel for adult patients regardless of geographic locale Rh, rhesus; H. pylori, Helicobacter pylori; HIV, human immunodeficiency virus; HCV, hepatitis C virus; PCR, polymerase chain reaction; CMV, cytomegalovirus; TPO, thrombopoietin; PaIgG, platelet associated immunoglobulin G
9 Changes from previous guidelines Bone marrow examination is appropriate in patients >60 years old and in patients not responding to first-line therapy options HIV and HCV and H. pylori should be routinely tested in adult patients Quantitative Ig level testing is indicated to exclude an immune deficiency syndrome or when treatment with intravenous immunoglobulin is considered
10 Assessing the need for treatment Complex analysis Involves Actual bleeding Patient s age (risk of bleeding) Patient s lifestyle (quality of life) Need for safe counts during surgery
11 Management of ITP: Watch and wait Mortality rate <<1% No indication for therapy if: no symptoms or signs are present platelets > 30 x 10 9 /l (Grade C)
12 Initial treatment for newly-diagnosed ITP Corticosteroids is the standard first-line treatment for adults with ITP who need treatment and do not have a relative contraindication to its use (e.g. diabetes, psychiatric disorders). IVIg or IV anti-d may be appropriate in patients with bleeding, at high risk of bleeding, and those who are unresponsive or have contraindications to steroids (e.g. insulin-dependent diabetes). Previous guidelines: same
13 Emergency treatment (on-demand treatment) High-dose IV corticosteroids IVIg Platelet transfusions Previous guidelines: same
14 Second-line therapy Medical TPO-receptor agonists - NEW Mycophenolate Rituximab Other Immunosuppressive agents Danazol Dapsone Surgical Splenectomy
15 Second-line therapy in adults medical TPO-receptor agonists Grade A recommendation, Evidence level Ib Response 80-85%. Cessation of treatment will lead to return of thrombocytopenia in most cases.
16 Second-line therapy in adults medical Rituximab Grade B recommendation, Evidence level IIa Initial response ~50%. Long-term durable responses in 15 20% Hepatitis B status needs to be determined prior to treatment (Grade C recommendation, Evidence level IV).
17 Second-line therapy in adults medical Immunosuppressive agents Include cyclosporin A, mycophenolate mofetil, cyclophosphamide and azathioprine. Variable responses Danazol and dapsone useful in elderly patients and in those in whom splenectomy is contraindicated (Grade B recommendation, Evidence level IIa/IIb).
18 Second-line therapy in adults Splenectomy Historically, the treatment with the highest likelihood of producing cure Wait at least 6 months from diagnosis (chance of spontaneous remission) Indium-labeled autologous platelet scanning may be useful prior to splenectomy to confirm that the spleen is the main site of platelet sequestration (Grade B recommendation, Evidence level III).
19 Splenectomy in ITP Indicated in case of: 1 Severe thrombocytopenia (Plt <10-20 x 10 9 /L) High risk of bleeding for Plt counts <30 x 10 9 /L Requirement of continuous glucocorticoid therapy to maintain safe platelet counts CR rate of 66%; OR 88% 2 Mortality rate with laparoscopic splenectomy 0.2% 2 Potential lifelong infection risk 1. Stasi et al. Thromb Haemost 2008;99: Kojouri et al. Blood 2004;104:
20 Adults failing first- and second-line therapies TPO-receptor agonists (romiplostim and eltrombopag - NEW Grade A recommendation, Evidence level Ib Miscellaneous (combination chemotherapy, campath-1h and HSCT) The side effects of these treatment options may be severe and the data supporting their use are limited Grade B recommendation; Evidence level IIb
21 ITP during pregnancy 1 line: oral corticosteroids or IVIg Grade C recommendation IV anti-d in Rh(D)-positive nonsplenectomized women appears to be well tolerated and effective based on results from a pilot study Grade B recommendation, Evidence Level IIb Previous guidelines: same
22 Management of delivery and newborn infants The mode of delivery must be determined by obstetric indications Grade B recommendation Cordocentesis and fetal scalp blood sampling should be avoided in the management of ITP in pregnancy Grade C recommendation Previous guidelines: same
23 Childhood ITP Clinical classification should be used to define disease severity - NEW Evidence level IIb, Grade B recommendation Treatment should be considered based on a combination of clinical symptoms, the circulating platelet count and impact of ITP on the patient s quality of life Evidence level IIb, Grade B recommendation
24 Grade of severity and management of children with ITP Bleeding/quality of life Grade 1. Minor bleeding, few petechiae ( 100 total) and/or 5 small bruises ( 3 cm diameter); no mucosal bleeding Grade 2. Mild bleeding, many petechiae (>100 total) and/or >5 large bruises (>3 cm diameter); no mucosal bleeding Grade 3. Moderate bleeding, overt mucosal bleeding, troublesome lifestyle Management approach Consent for observation Consent for observation or for treatment in selected children Intervention to reach Grade 1/2 in selected children Grade 4. Mucosal bleeding or suspected internal hemorrhage Intervention Modified from Buchanan & Adix; Bolton-Maggs & Moon; Imbach et al
25 First-line treatments in childhood ITP IVIg and anti-d can raise the platelet count rapidly. Grade A recommendation, Evidence level Ib Anti-D 75 μg/kg has similar efficacy to IVIg and is rarely associated with severe hemolysis Grade A recommendation, Level Ib evidence PDN 1 2 mg/kg/day of prednisone may be given, with treatment titrated against the platelet count Grade A recommendation, Evidence level Ib Alternatively, a higher dose of corticosteroids 4 mg/kg/day for 4 days may be used Grade B recommendation, Evidence level III
26 Treatment options in children with persistent or chronic ITP Pulsed high-dose steroids or regular IVIg/anti-D may control bleeding while awaiting spontaneous remission or while considering disease-altering treatment. Rituximab Grade B recommendation, Evidence level IIa and IIb TPO-receptor agonists Grade C recommendation, Evidence Level IV Combination therapies (see adult section) Grade C recommendation, Evidence Level IIb, III
27 Splenectomy in children with chronic ITP Rarely indicated in childhood ITP Grade C recommendation It may be justified for children with chronic unremitting and severe ITP with bleeding symptoms, whose disease has been present for more than months resulting in impairment of their quality of life Grade B recommendation, Evidence level IIb Previous guidelines: same
28 New Guidelines: Conclusions (1) Few substantial changes Diagnosis: still of exclusion; more emphasis on screening for infections Adults: 1st line therapy: no change (CS, IVIG, Anti-D) 2nd line therapy: TPO-R agonists if contraindications to splenectomy 3rd line therapy: TPO-R agonists
29 New Guidelines: Conclusions (2) Childhood ITP: Clinical classification to define disease severity 1st and 2nd line therapy: no change 3rd line therapy: Rituximab 4th line therapy: TPO-R agonists; splenectomy usually not considered Pregnancy: No change Target platelet count for surgery: No change
30 TPO peptide mimetics: Romiplostim (nplate ) No sequence similarity to natural TPO Therefore, does not elicit anti-tpo antibodies
31 Romiplostim: Mechanism of Action romiplostim thrombopoietin receptor inactive receptor active receptor Cell membrane P SHC GRB2 P SOS RAS/RAF Cytoplasm STAT P P JAK MAPKK p42/44 Signal Transduction Increased platelet production
32 Romiplostim (AMG 531) in healthy volunteers Phase I study Wang et al. Clin Pharmacol Ther 2004;76:628-38
33 Comparison of platelet responses in subjects receiving single IV or SC administration Wang et al. Clin Pharmacol Ther 2004;76:628-38
34 Romiplostim (AMG 531) in chronic ITP Phase I-II studies Bussel et al. New Engl J Med 2006;371:
35 Peak Individual Platelet Counts in Phase I The shaded area shows the targeted platelet range Bussel et al. New Engl J Med 2006;371:
36 Peak Individual Platelet Counts in Phase II The shaded area shows the targeted platelet range Bussel et al. New Engl J Med 2006;371:
37 Romiplostim in Chronic ITP Phase III study Weekly, s.c. romiplostim in slowly escalating doses (1 µg/kg up to 15 µg/kg) for 24 weeks Dose adjusted to achieve a platelet count of 50, ,000 Inclusion criteria: Age 18; ITP with platelet count <30,000 Other treatments were discontinued at least 4 weeks before entry Randomized, double-blind, Phase 3 trial (n = 125) Splenectomy (n = 63) Non-splenectomized (n = 62) Placebo (n = 21) Romiplostim 1 mcg/kg SQ q wk, target Plt x10 9 /L (n = 42) Placebo (n = 21) Romiplostim 1 mcg/kg SQ q wk, target Plt x109/L (n = 41) Kuter DJ et al. Lancet 2008;371:
38 Platelet Counts Splenectomised Range = middle 2 quartiles Non-splenectomised Kuter et al. Lancet. 2008;371:
39 Dose Adjustments Target platelet count 50, ,000 Splenectomised ±SEM Non-splenectomised Kuter et al. Lancet. 2008;371:
40 Definition of platelet response Durable Platelets 50,000/µL for at least 6 of the last 8 weeks of treatment Transient Four or more weekly platelet responses (Plt 50,000/µL) at any time during the study Kuter et al. Lancet. 2008;371:
41 Phase III: Overall Platelet Response Overall Platelet Response, % 100 Placebo Romiplostim (P<.0001) (P<.0001) (P<.0001) Splenectomized Nonsplenectomized Total Kuter DJ, et al. Lancet.2008;371(9610):
42 Patients receiving rescue therapies Kuter et al. Lancet. 2008;371:
43 Adverse Events Placebo Romiplostim Severe or lifethreatening bleeding 5/41 (12%) 6/84 (7%) Thrombosis 1 1 popliteal art. thrombosis 1 CVA Death 1 ICH 1 PE 1 ICH after starting aspirin to treat thrombosis Increased bone marrow reticulin 1 (reversible) Kuter et al. Lancet. 2008;371:
44 Romiplostim Long-term Treatment S C R E E N I N G Treatment Period Romiplostim starting dose: 1 µg/kg or last dose on prior study Individual dose adjustment based on platelet count Target platelet count: x10 9 /L Maximum dose 10 µg/kg* Reductions in concurrent ITP therapies allowed when platelet counts > 50 x 10 9 /L Rescue medications allowed * A small number of patients are on doses up to 17 µg/kg. Initial maximal dose 30 µg/kg, later reduced to 15 µg/kg, and then 10 µg/kg. I N T E R I M A N AL Y S I S Day - 8 Day 1 Study drug administered SC weekly End of Study Longest continuously reported active treatment study with a TPO mimetic Bussel JB, Kuter DJ et al. Blood 2007;110: abstract 568
45 Bussel et al. Blood. 2009;113: Long term treatment
46 Potential Adverse Consequence of Thrombopoietic Growth Factors Thrombocytosis Thrombosis Stimulation of tumor growth Stimulation of leukemia cell growth Interactions with other cytokines Autoantibody formation Stem cell depletion Reduction in threshold for platelet activation Rebound worsening of thrombocytopenia Increased bone marrow reticulin
47 Increased Bone Marrow Reticulin 11 of 210 patients in romiplostim studies showed increased reticulin No chromosome abnormalities Many at high doses (>10 µg/kg) Many with minimal response to drug Decreased in two who had subsequent bone marrow
48 Conclusions Romiplostim has no sequence homology to endogenous TPO Romiplostim has the same mechanism of action of TPO Romiplostim given once a week subcutaneously for 24 weeks produces a durable platelet response in ~40% of splenectomized and ~60% of non-splenectomized patients with ITP and allows discontinuation of other medications in many patients The drug is well tolerated Long-term treatment appears feasible
Ruolo dei nuovi agenti trombopoietici nella terapia dell ITP
42 CONGRESSO NAZIONALE SIE Società Italiana di Ematologia Milano, MIC Centre, 18-21 ottobre 2009 Ruolo dei nuovi agenti trombopoietici nella terapia dell ITP Dr. Roberto Stasi Department of Haematology
More informationContemporary perspectives and initial management of pediatric ITP. William Beau Mitchell, MD Weill Cornell Medical College New York, NY USA
Contemporary perspectives and initial management of pediatric ITP William Beau Mitchell, MD Weill Cornell Medical College New York, NY USA Case Presentation 5 year old female Bruises on trunk, extremities
More informationIdiophatic Thrombocytopenic Purpura: Current Concepts In Pathophysiology And Management
Slovenian Society of Hematology Kranjska Gora, 3-4 October 2008 Idiophatic Thrombocytopenic Purpura: Current Concepts In Pathophysiology And Management Dr. Roberto Stasi S.C. di Oncologia ed Ematologia
More informationDr Kannan S Consultant Hematologist Sahyadri Speciality Hospital, Pune K E M Hospital, Pune
IMMUNE THROMBOCYTOPENIA Dr Kannan S Consultant Hematologist Sahyadri Speciality Hospital, Pune K E M Hospital, Pune ITP Megakaryocytes Definition of ITP Primary immune thrombocytopenia Platelet count
More informationDiagnosis and Management of Immune Thrombocytopenias. Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016
Diagnosis and Management of Immune Thrombocytopenias Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016 Disclosures Research support: NIH, CDC, Eisai, Pfizer, Daiichi Sankyo, GlaxoSmithKline,
More informationExpert Review: Updates in Immune Thrombocytopenia. Reference Slides
Expert Review: Updates in Immune Thrombocytopenia Reference Slides Immune Thrombocytopenia (ITP): Overview ITP causality 1,2 Suboptimal platelet production Dysregulated adaptive immune system Increased
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Romiplostim Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 12/15/2017 Next
More informationUpdate on the Management of Immune Thrombocytopenic Purpura (ITP) Dr Raymond Wong Department of Medicine & Therapeutics Prince of Wales Hospital
Update on the Management of Immune Thrombocytopenic Purpura (ITP) Dr Raymond Wong Department of Medicine & Therapeutics Prince of Wales Hospital Immune Thrombocytopenia (ITP) Immune-mediated acquired disease
More informationTreatment pathway for adult patients with immune (idiopathic) thrombocytopenic purpura (ITP)
Prescribing Clinical Network Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) Crawley and Horsham & Mid-Sussex CCG Treatment pathway for adult
More informationthrombopoietin receptor agonists and University of Washington January 13, 2012
Tickle me eltrombopag: thrombopoietin receptor agonists and the regulation of platelet production Manoj Menon University of Washington January 13, 2012 Outline Clinical case Pathophysiology of ITP Therapeutic
More informationScottish Medicines Consortium
Scottish Medicines Consortium romiplostim, 250 microgram vial of powder for solution for subcutaneous injection (Nplate ) No. (553/09) Amgen 08 May 2009 (Issued 4 September 2009) The Scottish Medicines
More informationSecond line therapy for ITP should be TPO agonists. Nichola Cooper Imperial Health Care NHS Trust
Second line therapy for ITP should be TPO agonists Nichola Cooper Imperial Health Care NHS Trust COHEM 2012 Antiplatelet antibodies Platelet count after infusion with patient plasma Hours Days T cells
More informationQUICK REFERENCE Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
QUICK REFERENCE 2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP) Presented by the American Society of Hematology, adapted from: The American Society of
More informationScottish Medicines Consortium
Scottish Medicines Consortium eltrombopag, 25mg and 50mg film-coated tablets (Revolade ) No. (625/10) GlaxoSmithKline UK 09 July 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationTHE OLD AND THE NEW OF ITP. Alison Street Malaysia April 2010
THE OLD AND THE NEW OF ITP Alison Street Malaysia April 2010 The Harrington-Hollingsworth Experiment Harrington et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic
More informationThe ITP Patient Advocate
The ITP Patient Advocate A Resource for Your Journey With Chronic ITP Visit nplate.com for more information Issue Two Medical News About Nplate This issue looks at a recent 1-year Nplate medical study
More informationCynthia Fata, MD, MSPH 6/23/15
Cynthia Fata, MD, MSPH 6/23/15 Clinical case presentation Introduction to thrombopoietin Development of thrombopoietic agents Clinical Indications Eltrombopag use in aplastic anemia Future uses 33 yo F
More informationClinical decision making in ITP: When to treat and how to treat
Clinical decision making in ITP: When to treat and how to treat Beng Hock Chong MBBS,PhD,FRACP, FRCPA,FRCP Professor of Medicine, University of New South Wales, Sydney and Director of Hematology, St George
More informationPediatric Immune Thrombocytopenia (ITP) Cindy E. Neunert MD, MSCS Associate Professor, Pediatrics Columbia University Medical Center New York, NY
Pediatric Immune Thrombocytopenia (ITP) Cindy E. Neunert MD, MSCS Associate Professor, Pediatrics Columbia University Medical Center New York, NY Objectives Review the 2011 American Society of Hematology
More informationWhat is the next step after failure of steroids in ITP? Splenectomy & Rituximab
What is the next step after failure of steroids in ITP? Splenectomy & Rituximab Dr. Roberto Stasi Department of Haematology St George's Hospital and Medical School London Factors that contribute to ITP
More informationCase Presentation. A Case from the Clinic. Additional Data. Examination and Data 10/27/2013
Northwestern University Feinberg School of Medicine Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus: The Role of New Agents Disclosures: Advisory Board: Incyte Corporation Speaker
More informationImmune Thrombocytopenia (ITP)
Immune Thrombocytopenia (ITP) ITP - What is it? ITP is a blood disorder affecting platelets in the blood. Platelets are small cells in your blood that help your blood to clot. In ITP the body s immune
More informationCorso Nazionale di Aggiornamento in Ematologia Clinica Bolzano giugno 2009
Corso Nazionale di Aggiornamento in Ematologia Clinica Bolzano 18-19 giugno 2009 Nuove prospettive terapeutiche nelle piastrinopenie autoimmuni Marco Ruggeri UO Ematologia, Ospedale San Bortolo, Vicenza
More informationImmune Thrombocytopenia
Immune Thrombocytopenia David J. Kuter, MD, Dphil Massachusetts General Hospital 2015 Highlights of ASH in Asia Bangkok, Thailand February 28 March 1 Common Causes of Thrombocytopenia Infections Viral
More informationAcute Immune Thrombocytopenic Purpura (ITP) in Childhood
Acute Immune Thrombocytopenic Purpura (ITP) in Childhood Guideline developed by Robert Saylors, MD, in collaboration with the ANGELS team. Last reviewed by Robert Saylors, MD September 22, 2016. Key Points
More informationImmune Thrombocytopenia. A Practical Guide for Nurses and Other Allied Healthcare Professionals
Immune Thrombocytopenia A Practical Guide for Nurses and Other Allied Healthcare Professionals Contents Chapter 1: Overview of immune thrombocytopenia 3 Chapter 2: Identifying immune thrombocytopenia 7
More informationRemissions after long term use of romiplostim for immune thrombocytopenia
Published Ahead of Print on September 1, 2016, as doi:10.3324/haematol.2016.151886. Copyright 2016 Ferrata Storti Foundation. Remissions after long term use of romiplostim for immune thrombocytopenia by
More informationClinical Policy Bulletin: Romiplostim (Nplate)
Romiplostim (Nplate) Page 1 of 8 Aetna Better Health 2000 Market Suite Ste. 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Clinical Policy Bulletin: Romiplostim (Nplate) Number: 0768 Policy Aetna considers
More informationThrombocytopenia: a practial approach
Thrombocytopenia: a practial approach Dr. med. Jeroen Goede FMH Innere Medizin, Medizinische Onkologie, Hämatologie FAMH Hämatologie Chefarzt Hämatologie Kantonsspital Winterthur Outline Introduction and
More informationHematology, Transfusion and Cell Therapy
hematol transfus cell ther. 2018;40(1):50 74 Hematology, Transfusion and Cell Therapy www.rbhh.org Special article Guideline on immune thrombocytopenia in adults: Associação Brasileira de Hematologia,
More informationImmune Thrombocytopenic Purpura (ITP)
Patient information Immune Thrombocytopenic Purpura Immune Thrombocytopenic Purpura (ITP) This leaflet is for adult patients diagnosed with Immune Thrombocytopenic Purpura also known as Immune Thrombocytopenia
More informationTavalisse (fostamatinib disodium hexahydrate)
Tavalisse (fostamatinib disodium hexahydrate) Policy Number: 5.01.661 Last Review: 07/2018 Origination: 07/2018 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationUse of TPO mimetics for Indications Other Than ITP
Use of TPO mimetics for Indications Other Than ITP Mazyar Shadman, MD, MPH Discussant: Siobán Keel, MD Hematology Fellows Conference June 28, 2013 Thrombopoietin (TPO) and other c mpl ligands TPO mimetics
More informationCase Report: Sustained Partial Response to Thrombopoietin-Receptor Ago nist-romiplo stim-in Therapy of Refractory Chronic Immune Thrombocytopenia
Med. J. Cairo Univ., Vol. 83, No. 1, September: 747-751, 2015 www.medicaljournalofcairouniversity.net Case Report: Sustained Partial Response to Thrombopoietin-Receptor Ago nist-romiplo stim-in Therapy
More informationpregnant patients in the Nplate pregnancy registry by calling Adjust weekly dose by increments of 1 mcg/kg to achieve and maintain a
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. Nplate (romiplostim)
More informationREVIEW ARTICLE. Immune Thrombocytopenic Purpura ADARSH A K, LAKSHMI KRISHNA INTRODUCTION CLASSIFICATION
ADARSH A K, LAKSHMI KRISHNA REVIEW ARTICLE INTRODUCTION ITP or immune thrombocytopenic purpura is an autoimmune disorder characterized by increased platelet destruction & platelet count < 1 lakh. It is
More informationV.N. KARAZIN KHARKOV NATIONAL UNIVERSITY
V.N. KARAZIN KHARKOV NATIONAL UNIVERSITY Kharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine Immune thrombocytopenic purpura Abduyeva
More informationASH Draft Recommendations for Immune Thrombocytopenia
ASH Draft Recommendations for Immune Thrombocytopenia INTRODUCTION American Society of Hematology (ASH) guidelines are based on a systematic review of available evidence. Through a structured process,
More informationTechnology appraisal guidance Published: 27 April 2011 nice.org.uk/guidance/ta221
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura Technology appraisal guidance Published: 27 April 2011 nice.org.uk/guidance/ta221 NICE 2018. All rights reserved. Subject
More informationNPLATE (romiplostim) for injection, for subcutaneous use Initial U.S. Approval: 2008
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NPLATE safely and effectively. See full prescribing information for NPLATE. NPLATE (romiplostim)
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru180 Topic: Promacta, eltrombopag Date of Origin: May 8, 2009 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPTANT
More informationUKITP INITAL INFORMATION SHEET (2.4)
UKITP INITAL INFORMATION SHEET (2.4) Barts Health NHS Trust The Royal London Hospital Pathology and Pharmacy Building 80 Newark Street, London E1 2ES Centre for Haematology Institute of and Molecular Science
More informationNplate (romiplostim) For subcutaneous injection Initial U.S. Approval: 2008
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. Nplate (romiplostim)
More informationThrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary
Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit OBJECTIVE The intent of the prior authorization
More informationPromacta (eltrombopag)
Promacta (eltrombopag) Policy Number: 5.01.542 Last Review: 5/2018 Origination: 6/2013 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Promacta
More informationAntiphospholipid Antibody Syndrome: Management Issues for the Hematologist
Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March
More informationApproach to thrombocytopenia and management of ITP. Dr.Aby Abraham Dept of Clinical Haematology
Approach to thrombocytopenia and management of ITP Dr.Aby Abraham Dept of Clinical Haematology 04-08-2014 Causes of thrombocytopenia Thrombocytopenia Pseudo True Decreased production Increased destruction
More informationHemostatic System - general information
PLATELET DISORDERS Hemostatic System - general information Normal hemostatic system vessel wall circulating blood platelets blood coagulation and fibrynolysis Bleeding Diathesis inherited or acquired defects
More informationThe Role of Anti-D in the Management of Chronic and Secondary Forms of ITP
The Role of Anti-D in the Management of Chronic and Secondary Forms of ITP 473 82 The Role of Anti-D in the Management of Chronic and Secondary Forms of ITP MAURICE GILLES GENEREUX BACKGROUND Immune thrombocytopenic
More informationPlatelets, numbers and alternative functions Nichola Cooper Hammersmith Hospital Imperial College
Platelets, numbers and alternative functions 2018 Nichola Cooper Hammersmith Hospital Imperial College Discussion points today What do platelets do beyond clot formation? How are platelets made? How is
More informationManagement of Acute ITP in Children Fifteen Years Experience
Cronicon OPEN ACCESS EC PAEDIATRICS Research Article Management of Acute ITP in Children Fifteen Years Experience Jalil I Alezzi* Pediatric Department, College of Medicine, Hadhramout University, Yemen
More informationCase Report Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
Volume 2012, Article ID 318597, 4 pages doi:10.1155/2012/318597 Case Report Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia Maria Fernanda Gonzalez and Jonathan
More informationGOOD MORNING! Thursday, July Heidi Murphy, MD Leslie Carter-King, MD
GOOD MORNING! Thursday, July 10 2014 Heidi Murphy, MD Leslie Carter-King, MD PREP QUESTION Almost all infants experience a transient increase in bilirubin concentrations known as physiologic jaundice during
More informationNplate is a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection.
Nplate (romiplostim) Product Information Page 1 of 16 NAME OF THE MEDICINE Nplate is the Amgen Inc. trademark for romiplostim (rbe). DESCRIPTION Romiplostim, a member of the thrombopoietin (TPO) mimetic
More informationRituximab for the treatment of adults with idiopathic (immune) thrombocytopenic purpura (ITP)
Bedfordshire and Luton Joint Prescribing Committee Date: September 2015 Review date: September 2018 Bullletin 221: Rituximab (MabThera ) for the treatment of adults with idiopathic (immune) thrombocytopenic
More informationManagement of newly diagnosed immune thrombocytopenia: can we change outcomes?
IT ALL STARTS HERE: DISORDERS OF PRIMARY HEMOSTASIS Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Cindy E. Neunert Department of Pediatrics, Columbia University Medical
More informationCase Report Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist
Case Report Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist Mohamed E. Osman Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi
More informationPROMACTA (eltrombopag olamine) oral tablet and oral suspension
PROMACTA (eltrombopag olamine) oral tablet and oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationCorso di Ematologia di Laboratorio Istituto Tumori, Milano novembre 2010
Corso di Ematologia di Laboratorio Istituto Tumori, Milano 11-12 novembre 2010 Piastrinopenie Immuni: dalla patogenesi alla standardizzazione del percorso diagnostico e terapeutico Marco Ruggeri UO Ematologia,
More informationCurrent and evolving treatment strategies in adult immune thrombocytopenia
memo (2018) 11:241 246 https://doi.org/10.1007/s12254-018-0428-7 Current and evolving treatment strategies in adult immune thrombocytopenia Jan-Paul Bohn Michael Steurer Received: 31 May 2018 / Accepted:
More informationRituximab for the treatment of Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Rituximab for the treatment of Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) February 2015 2015 Summary Rituximab (MabThera,
More informationClinical profile of ITP in Children: A single center study
Clinical profile of ITP in Children: A single center study Dr.Ramadan Allalous 1,Dr Fathia Alriani 1, Dr Amna Rayani 2. 1Tripoli ' s Medical center,medical Faculty, Tripoli University 2Tripoli Children
More informationManagement of newly diagnosed immune thrombocytopenia: can we change outcomes?
REVIEW ARTICLE Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Cindy E. Neunert Department of Pediatrics, Columbia University Medical Center, New York, NY Immune thrombocytopenia
More informationDrug Class Review: Thrombocytopenia
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationN terminus (M1) C7 C10 C42 C102 C148 C206. C terminus (A269)
Nplate (romiplostim) Product Information Page 1 of 20 NAME OF THE MEDICINE Nplate is the Amgen Inc. trademark for romiplostim (rbe). N terminus (M1) C7 C10 Fc Domain (228 a.a.) CH2 C42 C102 CH3 C148 C206
More informationeltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationEfficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
BLOOD RESEARCH VOLUME 50 ㆍ NUMBER 1 March 2015 ORIGINAL ARTICLE Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia Yeo-Kyeoung Kim, Seung-Sin Lee, Sung-Hoon Jeong, Jae-Sook
More informationDrug Class Prior Authorization Criteria Immune Globulins
Drug Class Prior Authorization Criteria Immune Globulins Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy has been developed through review of
More informationUse of Intravenous Anti-RhD Immunoglobulin (RhIG) in the Treatment of Primary Immune Thrombocytopenia
Use of Intravenous Anti-RhD Immunoglobulin (RhIG) in the Treatment of Primary Immune Thrombocytopenia KRISTINA WILLIAMS ABSTRACT Commercialized intravenous immunoglobulin (IVIG) products have been used
More informationMost Common Hemostasis Consults: Thrombocytopenia
Most Common Hemostasis Consults: Thrombocytopenia Cindy Neunert, MS MSCS Assistant Professor, Pediatrics CUMC Columbia University TSHNA Meeting, April 15, 2016 Financial Disclosures No relevant financial
More informationMeasuring Thrombopoietin
Measuring Thrombopoietin - 2012 A New Tool for Hematologists? Mervyn A. Sahud, M.D. A.B.I.M.-Hem. Medical Director, Coagulation Department Quest Diagnostics Nichols Institute San Juan Capistrano, CA Disclosure
More informationBleeding Disorders.2 MS Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD
Bleeding Disorders.2 MS4.25.02.2019 Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD Email: abdalla.awidi@gmail.com Case 6: GT 18 yr old female was admitted with pallor, abdominal pain and gum
More informationEltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) This guidance
More informationSecond-line therapies in immune thrombocytopenia
WHEN ANTIBODY RESPONSE GOES AWRY Second-line therapies in immune thrombocytopenia Rachael F. Grace 1 and Cindy Neunert 2 1 Pediatric Hematology/Oncology, Dana-Farber/Boston Children s Cancer and Blood
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationINTRODUCTION TO SET FORTH APROACH TO MANAGING ADULTS TO SET FORTH APROACH PRIMARY ( PRIMARY AUTOIMMUNE) AUTOIMMUNE ITP FROM ASH & THE BRITISH
HOW I TREAT IDIOPATHIC THROMBOCYTOPENIC PURPURA Dauglas B. Cines, James B Bussel. Blood Oktober 2005:106(7):2244-22512251 INTRODUCTION TO SET FORTH APROACH TO MANAGING ADULTS PRIMARY (AUTOIMMUNE) ITP FROM
More informationRESEARCH. Department of Internal Medicine, Faculty of Health Sciences, University of Cape Town, South Africa 2
Role of splenectomy for immune thrombocytopenic purpura (ITP) in the era of new second-line therapies and in the setting of a high prevalence of HIV-associated ITP K R Antel, 1 MB ChB, FCP (SA), MMed (Med);
More informationIl Rituximab nella ITP
Il Rituximab nella ITP Monica Carpenedo U.O.C Ematologia e TMO, Ospedale San Gerardo, Monza Burning questions about Rituximab and ITP What is the mechanism of action? What is long term effect of treatment?
More informationAppendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014
Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag
More informationPlatelet Disorders. By : Saja Al-Oran
Platelet Disorders By : Saja Al-Oran Introduction The platelet arise from the fragmentation of the cytoplasm of megakaryocyte in the bone marrow. circulate in the blood as disc-shaped anucleate particles
More informationImmune thrombocytopenia: No longer idiopathic
take-home points from lectures by cleveland clinic and visiting faculty MEDICAL GRAND ROUNDS KEITH McCRAE, MD* Director, Benign Hematology, Department of Hematologic Oncology and Blood Disorders, Taussig
More informationAnn Janssens, MD, PhD. Department of Hematology, UZ Leuven BHS course 8 november 2014
Ann Janssens, MD, PhD Department of Hematology, UZ Leuven BHS course 8 november 2014 The history of platelets, megakaryocytes and thrombopoietin Platelet homeostasis etpo Production Platelet Pool Normal
More informationThrombocytopenia. Dr Lynda Vandertuin May 6, 2014
Dr Lynda Vandertuin May 6, 2014 1 Presentation 1. Definition 2. Platelet Physiology, Thromboiesis, & Platelet Function 3. Bleeding Risk 4. Clinical Diagnosis 5. Differential Diagnosis 6. Classification
More informationGeneral Heme. Tom DeLoughery, MD FACP. Oregon Health and Sciences University
General Heme Tom DeLoughery, MD FACP Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen, Alexion What I am Talking About ITP Sickle
More informationEltrombopag for the treatment of chronic immune thrombocytopenic purpura (ITP): A Single Technology Appraisal
Eltrombopag for the treatment of chronic immune thrombocytopenic purpura (ITP): A Single Technology Appraisal Produced by: Aberdeen HTA Group Authors: Ewen Cummins Shona Fielding Neil Scott 2 Kieran Rothnie
More informationDescription of the evidence collection method. (1). Each recommendation was discussed by the committee and a consensus
Special Article Guidelines on the treatment of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Sandra Regina Loggetto 1
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Nplate 125 micrograms powder for solution for injection Nplate 250 micrograms powder for solution for injection Nplate 500
More informationState of the art how I manage immune thrombocytopenia
review State of the art how I manage immune thrombocytopenia Nichola Cooper Hammersmith Hospital, Imperial College, London, UK Summary The management of patients with immune thrombocytopenia (ITP) is rapidly
More informationKeywords evidence evaluation, practice guidelines, conflicts of interest, immune thrombocytopenia
481618AJMXXX10.1177/1062860613481618American Journal of Medical QualityGeorge et al research-article2013 Article Conflicts of Interest and Clinical Recommendations: Comparison of Two Concurrent Clinical
More informationThe Evolving Role of Reticulated Platelets
The Evolving Role of Kyle Riding, PhD, MLS(ASCP) CM University of Central Florida Session Objectives Platelets Recall the process involved in megakaryopoiesis and thrombocytopoiesis Explain the various
More informationCancer Biology 2016;6(3) Immune Thrombocytopenia: Single Institute Experience. Mohammed A. Albalawi, MD
Immune Thrombocytopenia: Single Institute Experience Mohammed A. Albalawi, MD Medicine department, College of Medicine, Taibah University. Email: albalawi_21@hotmail.com Abstract: Immune thrombocytopenia
More informationNeutropenia Following Intravenous Immunoglobulin Therapy in Pediatric Patients with Idiopathic Thrombocytopenic Purpura
ORIGINAL ARTICLE IJBC 2014;6(2): 81-85 Neutropenia Following Intravenous Immunoglobulin Therapy in Pediatric Patients with Idiopathic Thrombocytopenic Purpura Ansari S * 1, Shirali A 1, Khalili N 1, Daneshfar
More informationPromacta. Promacta (eltrombopag) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.15 Subject: Promacta Page: 1 of 6 Last Review Date: September 15, 2017 Promacta Description Promacta
More informationA randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
CLINICAL TRIALS AND OBSERVATIONS A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia James B. Bussel, 1 George R. Buchanan, 2 Diane
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
23 October 2013 EMA/652909/2013 Oncology Working Party (ONCWP) Overview of comments received on Guideline on the clinical development of medicinal products intended for the treatment of chronic primary
More informationCurrent management of immune thrombocytopenia
DISORDERS OF PLATELET DESTRUCTION Current management of immune thrombocytopenia Cindy E. Neunert 1 1 Department of Pediatrics and Cancer Center, Georgia Regents University, Augusta, GA Immune thrombocytopenia
More informationThe Oklahoma ITP Registry Newsletter July 2011
The Oklahoma ITP Registry Newsletter July 2011 1 Hello! 1 The ITP Registry 1 Follow-Up Reminder 1 Dr. George s Perspective 3 Patient Stories: Rosie s Story 2010 Update 7 Send Your Suggestions 7 Resources
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More information